Clinical Trial Enrollment Crisis: 80% Miss Timelines, Few Cancer Patients Join
A new analysis quantifies the chronic shortfall in clinical trial participation, with most studies failing to enroll on schedule and cancer patient involvement remaining a rare event.
Clinical trials face a persistent and well-documented enrollment crisis, according to a presentation at the DPHARM conference. Data shared at the event indicate that about four out of five trials do not hit their enrollment deadlines. That delay creates cascading costs and slows the delivery of new treatments.
The participation gap is especially stark in oncology. Fewer than one in twenty eligible adult cancer patients enters a trial. That means the vast majority of patients who could contribute to medical research are not being reached by current recruitment efforts, even as the demand for faster drug development grows.
The numbers highlight a structural problem rather than a single point of failure. Patient awareness, site capacity, and trial design all play a role. While the source does not propose specific fixes, the scale of the shortfall suggests that incremental changes are unlikely to be enough.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.